A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands

Condition:   Advanced Solid Tumors With Overexpression of Epidermal Growth Factor Receptor (EGFR) or EGFR Ligands
Intervention:   Drug: ABBV-321
Sponsor:   AbbVie
Not yet recruiting - verified July 2017

http://ift.tt/2vlzKbo